The interaction between ER and NFκB in resistance to endocrine therapy

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Sas, Leen ^a,b   Lardon, Filip ^b   Vermeulen, Peter B ^a   Hauspy, Jan ^a   Van Dam, Peter ^a   Pauwels, Patrick ^b   Dirix, Luc Y ^a   Van Laere, Steven J ^a,c  

^a Oncology Centre of Antwerp   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ALLOPURINOL; ANASTROZOLE; ARZOXIFENE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; DEHYDROXYMETHYLEPOXYQUINOMYCIN; DROLOXIFENE; EPOXOMICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLAVOPIRIDOL; FULVESTRANT; IDOXIFENE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LETROZOLE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PARTHENOLIDE; PHOSPHOTRANSFERASE; PYRROLIDINE DITHIOCARBAMATE; QUINOMYCIN; RALOXIFENE; SN 50; TAMOXIFEN; TOREMIFENE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROTEIN BINDING;

BREAST CANCER; CANCER CELL; CANCER RESISTANCE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENETIC DISORDER; GENETIC TRANSCRIPTION; HORMONAL THERAPY; HUMAN; MOLECULAR INTERACTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NF-KAPPA B; PROTEIN BINDING; RECEPTORS, ESTROGEN;

EID: 84866145981     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3196     Document Type: Review

References (79)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
2. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA 2010, 107:6994-6999. 10.1073/pnas.0912708107, 2872436, 20335537.
3. Bertucci F, Birnbaum D. Reasons for breast cancer heterogeneity. J Biol 2008, 7:6. 10.1186/jbiol67, 2263121, 18304379.
4. Hsiao YH, Chou MC, Fowler C, Mason JF, Man YG. Breast cancer heterogeneity: mechanisms, proofs, and implications. J Cancer 2010, 1:6-13. 2931354, 20842218.
5. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007, 12:631-663. 10.1634/theoncologist.12-6-631, 17602054.
6. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569. 10.1056/NEJMoa052933, 16899776.
7. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006, 66:3903-3911. 10.1158/0008-5472.CAN-05-4363, 16585219.
8. Creighton CJ. A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene 2007, 26:4648-4655. 10.1038/sj.onc.1210245, 17213801.
9. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signalling with repression of classic estrogen receptor genomic function. Cancer Res 2008, 68:826-833. 10.1158/0008-5472.CAN-07-2707, 18245484.
10. Thomas RS, Sarwar N, Phoenix F, Coombes RC, Ali S. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity. J Mol Endocrinol 2008, 40:173-184. 10.1677/JME-07-0165, 2277492, 18372406.
11. Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or HER2 overexpression and MAPK hyperactivation. Br J Cancer 2007, 97:659-669. 10.1038/sj.bjc.6603906, 2360371, 17700572.
12. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 2000, 97:8542-8547. 10.1073/pnas.97.15.8542, 26984, 10900013.
13. Muramatsu M, Inoue S. Estrogen receptors: how do they control reproductive and nonreproductive functions?. Biochem Biophys Res Commun 2000, 270:1-10. 10.1006/bbrc.2000.2214, 10733896.
14. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR, Hanby AM. Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 2004, 5:174-181. 10.1016/S1470-2045(04)01413-5, 15003201.
15. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. The complete primary structure of human estrogen receptor beta (hERβ) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 1998, 243:122-126. 10.1006/bbrc.1997.7893, 9473491.
16. Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, Yoshida N, Yamaguchi Y. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 2003, 10:193-202. 10.1677/erc.0.0100193, 12790782.
17. Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 2010, 16:2702-2708. 10.1158/1078-0432.CCR-09-1753, 20427689.
18. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992, 89:4037-4041. 10.1073/pnas.89.9.4037, 525627, 1570330.
19. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004, 5:207-213. 10.1016/S1535-6108(04)00059-5, 15050912.
20. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802. 10.1056/NEJMoa032312, 14551341.
21. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001, 19:881-894.
22. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004, 11:643-658. 10.1677/erc.1.00776, 15613444.
23. Musgrove AE, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643. 10.1038/nrc2713, 19701242.
24. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094. 10.1158/0008-5472.CAN-09-3746, 2832818, 20179196.
25. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005, 12(Suppl 1):S99-S111.
26. Aguilar H, Solé X, Bonifaci N, Serra-Musach J, Islam A, López-Bigas N, Méndez-Pertuz M, Beijersbergen RL, Lázaro C, Urruticoechea A, Pujana MA. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 2010, 29:6071-6083. 10.1038/onc.2010.333, 20711236.
27. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008, 29:217-233. 2528847, 18216219.
28. Johnston SR. Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 2009, 9(Suppl 1):S28-S36.
29. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003, 9(Suppl 2):447S-454S.
30. Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bièche I. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 2003, 9:1259-1266.
31. Zhang ZH, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Ibusuki M, Tomita S, Sugiura H, Kobayashi S, Fujii Y, Iwase H. Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on Relapse. Chin Med J 2009, 122:1764-1768.
32. deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW, Weiss GR. NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 2004, 15:885-890. 10.1093/annonc/mdh232, 15151944.
33. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NFκB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 2005, 12(Suppl31):37-46.
34. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC. Enhanced NF B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007, 7:59-74. 10.1186/1471-2407-7-59, 1852565, 17407600.
35. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002, 109(Suppl):S81-96.
36. Karin M. How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene 1999, 18:6867-6874. 10.1038/sj.onc.1203219, 10602462.
37. Hoffmann A, Leung TH, Baltimore D. Genetic analysis of NF-κB/Rel transcription factors defines functional specificities. EMBO J 2003, 22:5530-5539. 10.1093/emboj/cdg534, 213788, 14532125.
38. Chen LF, Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 2004, 5:392-401. 10.1038/nrm1368, 15122352.
39. Sun SC. Non-canonical NF-κB signaling pathway. Cell Res 2011, 21:71-85. 10.1038/cr.2010.177, 3193406, 21173796.
40. Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Shen TL, Golubovskaya VM, Chang CC, Shyue SK, Liou JY. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci 2010, 86:199-206. 10.1016/j.lfs.2009.12.003, 20006625.
41. Sen R, Smale ST. Selectivity of the NF-κB response. Cold Spring Harb Perspect Biol 2010, 2:a000257. 10.1101/cshperspect.a000257, 2845200,2845200, 20452937.
42. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 2012, 12:121-132.
43. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
44. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-κB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15:416-428. 10.1016/j.ccr.2009.03.016, 2881229, 19411070.
45. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
46. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF- B, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706. 10.1016/j.cell.2009.10.014, 2783826, 19878981.
47. Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. Nuclear factor-κB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-κB DNA-binding. Clin Cancer Res 2006, 12:3249-3256. 10.1158/1078-0432.CCR-05-2800, 16740744.
48. Van Laere S, Limame R, Van Marck EA, Vermeulen PB, Dirix LY. Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments. Cancer 2010, 116(Suppl 11):2794-2805.
49. Wu L, Shao L, An N, Wang J, Pazhanisamy S, Feng W, Hauer-Jensen M, Miyamoto S, Zhou D. IKKβ regulates the repair of DNA double-strand breaks induced by ionizing radiation in MCF-7 breast cancer cells. PLoS One 2011, 6:e18447. 10.1371/journal.pone.0018447, 3072401, 21490922.
50. Belguise K, Sonenshein GE. PKCθ promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor α synthesis. J Clin Invest 2007, 117:4009-4021. 2082145, 18037997.
51. Ghisletti S, Meda C, Maggi A, Vegeto E. 17β-Estradiol inhibits inflammatory gene expression by controlling NF-κB intracellular localization. Mol Cell Biol 2005, 25:2957-2968. 10.1128/MCB.25.8.2957-2968.2005, 1069609, 15798185.
52. Galien R, Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-κB site. Nucleic Acids Res 1997, 25:2424-2429. 10.1093/nar/25.12.2424, 146754, 9171095.
53. Nettles KW, Gil G, Nowak J, Métivier R, Sharma VB, Greene GL. CBP is a dosage-dependent regulator of nuclear factor-κB suppression by the estrogen receptor. Mol Endocrinol 2008, 22:263-272. 2234588, 17932106.
54. Paimela T, Ryhänen T, Mannermaa E, Ojala J, Kalesnykas G, Salminen A, Kaarniranta K. The effect of 17β-estradiol on IL-6 secretion and NF-κB DNA-binding activity in human retinal pigment epithelial cells. Immunol Lett 2007, 110:139-144. 10.1016/j.imlet.2007.04.008, 17532054.
55. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130. 10.1016/j.ccr.2007.07.004, 2730509, 17692804.
56. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
57. Qiu J, Wang X, Guo X, Zhao C, Wu X, Zhang Y. Toll-like receptor 9 agonist inhibits ERa-mediated transactivation by activating NF-κB in breast cancer cell lines. Oncol Rep 2009, 22:935-941.
58. Hsu SM, Chen YC, Jiang MC. 17 beta-estradiol inhibits tumor necrosis factor-alpha-induced nuclear factor-kappa B activation by increasing nuclear factor-kappa B p105 level in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2000, 279:47-52. 10.1006/bbrc.2000.3891, 11112416.
59. Dai R, Phillips RA, Ahmed SA. Despite inhibition of nuclear localization of NF-κB p65, c-rel, and RelB, 17-β estradiol up-regulates NF-κB signalling in mouse splenocytes: the potential role of Bcl-3. J Immunol 2007, 179:1776-1783.
60. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 2006, 21:555-564. 10.1016/j.molcel.2006.01.014, 16483936.
61. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007, 9:470-478. 10.1038/ncb1559, 2394707, 17369819.
62. Acharyya S, Sharma SM, Cheng AS, Ladner KJ, He W, Kline W, Wang H, Ostrowski MC, Huang TH, Guttridge DC. TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in Duchenne muscular dystrophy. PLoS One 2010, 5:e12479. 10.1371/journal.pone.0012479, 2930001, 20814569.
63. Reijm EA, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, van Gelder ME, Sieuwerts AM, Sleijfer S, Foekens JA, Berns EM. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat 2011, 125:387-394. 10.1007/s10549-010-0836-9, 20306127.
64. Wang X, Belguise K, O'Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V, Chalbos D, Sonenshein GE. RelB NF-κB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol Cell Biol 2009, 29:3832-3834. 10.1128/MCB.00032-09, 2704748, 19433448.
65. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF-κB cooperativity at adjacent response elements. J Biol Chem 2010, 285:31100-31106. 10.1074/jbc.M110.155309, 2951183, 20705611.
66. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin CY, Stanculescu A. Positive cross-talk between estrogen receptor and NF-κB in breast cancer. Cancer Res 2009, 69:8918-8925. 10.1158/0008-5472.CAN-09-2608, 2996265, 19920189.
67. Frasor J, Weaver AE, Pradhan M, Mehta K. Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17β-estradiol and proinflammatory cytokines. Endocrinology 2008, 149:6272-6279. 10.1210/en.2008-0352, 18703630.
68. Rubio MF, Werbajh S, Cafferata EG, Quaglino A, Colo GP, Nojek IM, Kordon EC, Nahmod VE, Costas MA. TNF-α enhances estrogen-induced cell proliferation of estrogen-dependent breast tumour cells through a complex containing nuclear factor-κB. Oncogene 2006, 25:1367-1377. 10.1038/sj.onc.1209176, 16331275.
69. Daosukho C, Kiningham K, Kasarskis EJ, Ittarat W, St Clair DK. Tamoxifen enhancement of TNF-alpha induced MnSOD expression: modulation of NF-κB dimerization. Oncogene 2002, 21:3603-3610. 10.1038/sj.onc.1205448, 12032862.
70. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB. Formation of an IKKα-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 2005, 18:71-82. 10.1016/j.molcel.2005.03.006, 15808510.
71. Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, Murphy LC. Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res 2006, 66:10162-10170. 10.1158/0008-5472.CAN-05-4111, 17047081.
72. Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, O'Malley BW. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell 2004, 15:937-949. 10.1016/j.molcel.2004.08.019, 15383283.
73. Tu Z, Prajapati S, Park KJ, Kelly NJ, Yamamoto Y, Gaynor RB. IKK alpha regulates estrogen-induced cell cycle progression by modulating E2F1 expression. J Biol Chem 2006, 281:6699-6706. 10.1074/jbc.M512439200, 16407216.
74. Kim MR, Choi HK, Cho KB, Kim HS, Kang KW. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci 2009, 100:1834-1841. 10.1111/j.1349-7006.2009.01260.x, 19681904.
75. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010, 28:1287-1293. 10.1200/JCO.2009.25.7246, 20124171.
76. Shih VF, Tsui R, Caldwell A, Hoffmann A. A single NFκB system for both canonical and non-canonical signaling. Cell Res 2011, 21:86-102. 10.1038/cr.2010.161, 3193412, 21102550.
77. Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R. BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J 2010, 24:2040-2055. 10.1096/fj.09-138305, 2874480, 20154269.
78. Riggins RB, Zwart A, Nehra R, Clarke R. The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; Fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 2005, 4:33-41.
79. Trinh XB, Sas L, Van Laere SJ, Prové A, Deleu I, Rasschaert M, van de Velde H, Vinken P, Vermeulen PB, van Dam PA, Wojtasik A, De Mesmaeker P, Tjalma WA, Dirix LY. A phase II study of the combination of endocrine treatment and Bortezomib in patients with endocrine resistant metastatic breast cancer. Oncol Rep 2011, 27:657-663.